生物试剂
>
生化试剂
>
信号通路
> SN50
加入收藏 取消收藏

SN50  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：1mg 5mg in glass bottle
溶解性：溶于水(50mg/mL超声）
产品描述：基本信息 产品编号： S11216 产品名称： SN50 CAS: 213546-53-3   储存条件 粉末 -20℃ 四年     分子式： C129H230N36O29S 溶于液体 -80℃ 6个月 分子量： 2781.50 -20℃ 1个月 化学名：  Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro Solubility (25°C)：   体外:   DMSO 100mg/mL (35.95mM) Ethanol 100mg/mL (35.95mM) Water 100mg/mL (35.95mM) 体内(现配现用):   ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 0.3595mL 1.7976mL 3.5952mL 5mM 0.0719mL 0.3595mL 0.7190mL 10mM 0.0360mL 0.1798mL 0.3595mL   生物活性 产品描述 一种可渗透细胞的NF-κB易位抑制剂。 靶点 NF-κB 体外研究 Pretreatment with SN50 results in a significant reduction in amount of PI-positive cells at 12,24,and 48h time-point post TBI compared with vehicle-treated groups.Topical SN50 suppresses nuclear factor-κB activation in local cells and reduces the incidence of epithelial defects/ulceration in healing corneas.Myofibroblast generation,macrophage invasion,activity of matrix metalloproteinases,basement membrane destruction,and expression of cytokines are all decreased in treated corneas compared with controls.Treating the human gastric cancer cells SGC7901 with SN50 could significantly enhance the effects of LY294002 on inducing cell death after 24h.SN50 can inhibit translocation of NF-kB and production of inflammatory cytokines that are implicated in lipopolysaccharide (LPS)-induced lung injury. 体内研究 Treatment with SN50 accelerates the recovery of motor functional outcome from 1st to 4th day.Animals subjected to SN50 pretreatment demonstrate a significant decrease in the visuospatial learning latencies relative to the control group at 7 and 8 days post-TBI.Pretreatment with SN50 results in a significant reduction of NF-κB p65 protein levels from 6 to 48 h post-TBI and TNF-a protein levels from 12 to 48h post-TBI.   推荐实验方法(仅供参考) 细胞实验:   SN50 is diluted in distilled sterilization water to create a stock solution.The final concentration of the SN50 solution used is 18µM.Cell viability is assessed with MTT assay.To determine the effects of SN50 on enhancing the role of LY294002 on SGC7901 cells,cells are plated into 96-well microplates (7×1000 cells/well) and cultured for 24h.Then LY294002 (50µM),SN50 (18µM) and LY294002+SN50 are added to the culture medium and cell viability is assessed with MTT 24h after drug treatment.   动物实验:   Mice:SN50 is prepared in saline (total volume:1μL,concentration:0.1μg/μL).SN50 is administered into the ipsilateral cerebral ventricle 10 min before TBI.After TBI,the bone flap is replaced,the scalp incision is sutured,and then mice are allowed to awaken and returned to their cages.Mice are killed at 1,6,12,24,48,and 72h after operation.Loss of plasmalemma integrity is evaluated by intraperitoneal injection of PI 1h before killing the animal.
保存条件：-20℃

猜你喜欢